Antiangiogenic properties of prostate-specific antigen (PSA)

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 69, Issue 4, 2009, Pages 447-451

  Mattsson, Johanna M ^a   Laakkonen, Pirjo ^b   Stenman, Ulf Håkan ^a   Koistinen, Hannu ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

HUVEC; KLK3; prostate cancer

Indexed keywords

ANGIOSTATIN; ENDOSTATIN; MONOCLONAL ANTIBODY; PROSTAGLANDIN F; PROSTATE SPECIFIC ANTIGEN; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIGEN EXPRESSION; CANCER GROWTH; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ANIMALS; HUMANS; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE-SPECIFIC ANTIGEN;

EID: 67651176106     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510903056031     Document Type: Review

References (49)

1. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev. 2001;22(2):184-204.
2. Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP, Fritz H, Lilja H, Malm J, Maltais LJ, Olsson AY, Petraki C, Scorilas A, Sotiropoulou G, Stenman UH, Stephan C, Talieri M, Yousef GM. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem. 2006;387(6):637-41.
3. Lövgren J, Rajakoski K, Karp M, Lundwall A, Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun. 1997;238(2):549-55.
4. Paju A, Bjartell A, Zhang WM, Nordling S, Borgström A, Hansson J, Stenman UH. Expression and characterization of trypsinogen produced in the human male genital tract. Am J Pathol. 2000;157(6):2011-21.
5. Pampalakis G, Sotiropoulou G. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim Biophys Acta. 2007;1776(1):22-31.
6. Takayama TK, Fujikawa K, Davie EW. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem. 1997;272(34):21582-8.
7. Emami N, Diamandis EP. Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade. Possible function in seminal plasma and skin. J Biol Chem. 2008;283(6):3031-41.
8. Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA. 1986;83(10):3166-70.
9. Coombs GS, Bergstrom RC, Pellequer JL, Baker SI, Navre M, Smith MM, Tainer JA, Madison EL, Corey DR. Substrate specificity of prostate-specific antigen (PSA). Chem Biol. 1998;5(9):475-88.
10. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest. 1985;76(5):1899-903.
11. Robert M, Gibbs BF, Jacobson E, Gagnon C. Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I. Biochemistry. 1997;36(13):3811-9.
12. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer. 2004;4(11):876-90.
13. Clements JA, Willemsen NM, Myers SA, Dong Y. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci. 2004;41(3):265-312.
14. Williams SA, Singh P, Isaacs JT, Denmeade SR. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate. 2007;67(3):312-29.
15. Koistinen H, Närvänen A, Pakkala M, Hekim C, Mattsson JM, Zhu L, Laakkonen P, Stenman UH. Development of peptides specifically modulating the activity of KLK2 and KLK3. Biol Chem. 2008;389(6):633-42.
16. Stege R, Grande M, Carlstrom K, Tribukait B, Pousette A. Prognostic signifi cance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res. 2000;6(1):160-5.
17. Abrahamsson PA, Lilja H, Falkmer S, Wadstrom LB. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate. 1988;12(1):39-46.
18. Paju A, Hotakainen K, Cao Y, Laurila T, Gadaleanu V, Hemminki A, Stenman UH, Bjartell A. Increased expression of Tumor-Associated Trypsin Inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol. 2007;52(6):1670-9.
19. Stenman UH, Leinonen J, Zhang WM, Finne P. Prostate-specific antigen. Semin Cancer Biol. 1999;9(2):83-93.
20. Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, Boccon-Gibod L, Ekman P. Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol. 2005;(Suppl. 216):64-81.
21. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8(4):268-78.
22. Emami N, Diamandis EP. Human tissue kallikreins: a road under construction. Clin Chim Acta. 2007;381(1):78-84.
23. Kubota Y, Kleinman HK, Martin GR, Lawley TJ. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol. 1988;107(4):1589-98.
24. Mattsson JM, Valmu L, Laakkonen P, Stenman UH, Koistinen H. Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid. Prostate. 2008;68(9):945-54.
25. Fortier AH, Nelson BJ, Grella DK, Holaday JW. Antiangio-genic activity of prostate-specific antigen. J Natl Cancer Inst. 1999;91(19):1635-40.
26. Fortier AH, Holaday JW, Liang H, Dey C, Grella DK, Holland-Linn J, Vu H, Plum SM, Nelson BJ. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. Prostate. 2003;56(3):212-9.
27. Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate. 2001;48(1):1-6.
28. Koistinen H, Wohlfahrt G, Mattsson JM, Wu P, Lahdenpera J, Stenman UH. Novel small molecule inhibitors for prostate-specific antigen. Prostate. 2008;68(11):1143-51.
29. Wu P, Leinonen J, Koivunen E, Lankinen H, Stenman UH. Identifi cation of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur J Biochem. 2000;267(20):6212-20.
30. Heidtmann HH, Nettelbeck DM, Mingels A, Jager R, Welker HG, Kontermann RE. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer. 1999;81(8):1269-73.
31. Cao Y. Endogenous angiogenesis inhibitors and their thera peutic implications. Int J Biochem Cell Biol. 2001;33(4):357-69.
32. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res. 2005;65(10):3967-79.
33. Ishii K, Otsuka T, Iguchi K, Usui S, Yamamoto H, Sugimura Y, Yoshikawa K, Hayward SW, Hirano K. Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion. Cancer Lett. 2004;207(1):79-87.
34. Pezzato E, Sartor L, Dell'Aica I, Dittadi R, Gion M, Belluco C, Lise M, Garbisa S. Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-)epigallocatechin-3-gallate. Int J Cancer. 2004;112(5):787-92.
35. Webber MM, Waghray A, Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res. 1995;1(10):1089-94.
36. Mattsson JM, Laakkonen P, Kilpinen S, Stenman UH, Koistinen H. Gene expression changes associated with the antiangiogenic activity of kallikrein-related peptidase 3 (KLK3) on human umbilical vein endothelial cells. Biol Chem. 2008;389(6):765-71.
37. Bindukumar B, Schwartz SA, Nair MP, Aalinkeel R, Kawinski E, Chadha KC. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia. 2005;7(3):241-52.
38. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA. 1998;95(11):6355-60.
39. Leu SJ, Lam SC, Lau LF. Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells. J Biol Chem. 2002;277(48):46248-55.
40. Glesne DA, Zhang W, Mandava S, Ursos L, Buell ME, Makowski L, Rodi DJ. Subtractive transcriptomics: establishing polarity drives in vitro human endothelial morphogenesis. Cancer Res. 2006;66(8):4030-40.
41. Schoenfeld J, Lessan K, Johnson NA, Charnock-Jones DS, Evans A, Vourvouhaki E, Scott L, Stephens R, Freeman TC, Saidi SA, Tom B, Weston GC, Rogers P, Smith SK, Print CG. Bioinformatic analysis of primary endothelial cell gene array data illustrated by the analysis of transcriptome changes in endothelial cells exposed to VEGF-A and PlGF. Angiogenesis. 2004;7(2):143-56.
42. Cline EI, Bicciato S, DiBello C, Lingen MW. Prediction of in vivo synergistic activity of antiangiogenic compounds by gene expression profi ling. Cancer Res. 2002;62(24):7143-8.
43. Wu P, Zhu L, Stenman UH, Leinonen J. Immunopeptidometric assay for enzymatically active prostate-specific antigen. Clin Chem. 2004;50(1):125-9.
44. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab. 1992;75(4):1046-53.
45. Koistinen H, Paju A, Koistinen R, Finne P, Lövgren J, Wu P, Seppälä M, Stenman UH. Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3. Prostate. 2002;50(2):112-8.
46. Sutkowski DM, Goode RL, Baniel J, Teater C, Cohen P, McNulty AM, Hsiung HM, Becker GW, Neubauer BL. Growth regulation of prostatic stromal cells by prostate-specific antigen. J Natl Cancer Inst. 1999;91(19):1663-9.
47. Dallas SL, Zhao S, Cramer SD, Chen Z, Peehl DM, Bonewald LF. Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J Cell Physiol. 2005;202(2):361-70.
48. Killian CS, Corral DA, Kawinski E, Constantine RI. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun. 1993;192(2):940-7.
49. Papadopoulos I, Sivridis E, Giatromanolaki A, Koukourakis MI. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. Clin Cancer Res. 2001;7(6):1533-8.